GUIDELINES (JSH 2009)

References

Hypertension Research (2009) **32**, 91–107; doi:10.1038/hr.2008.15

- Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. *J Atheroscler Thromb* 2007; **14**: 278–286. RV
- Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. *Stroke* 2003; **34**: 2349–2354. OS
- Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, Nakamura M, Shimamoto T, Komachi Y. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. *Am J Med* 2002; **112**: 104–109. OS
- Kimura Y, Takishita S, Muratani H, Kinjo K, Shinzato Y, Muratani A, Fukiyama K. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. *Intern Med* 1998; **37**: 736–745. OS
- Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S, Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707–716. MA
- Nippon Data 80 Research Group. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese—Nippon data 80. *J Hum Hypertens* 2003; **17**: 851–857. OS
- Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. *Stroke* 2000; **31**: 2616–2622. OS
- Arima H, Tanizaki Y, Kiyohara Y, Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M, Iida M. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. *Arch Intern Med* 2003; **163**: 361–366. OS
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903–1913. MA
- Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. *Hypertens Res* 2004; **27**: 21–30. RT
- Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. *Kidney Int* 2005; **68**: 228–236. OS
- Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, Saitoh S, Sakata K, Okayama A, Ueshima H, The NIPPON DATA90 Research Group. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. *Circ J* 2006; **70**: 954–959. OS
- Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T, Shimamoto K. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program—Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. *Hypertens Res* 2005; **28**: 203–208. OS
- Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. *Stroke* 2007; **38**: 1744–1751. OS
- Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, Hirakata H, Iida M. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. *Am J Kidney Dis* 2006; **48**: 383–391. OS
- Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, Arima H, Tsuruyama K, Iida M, Kiyohara Y. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. *Stroke* 2007; **38**: 2063–2069. OS
- Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Saitoh S, Okayama A, Ueshima H, The NIPPON DATA 80 Research Group. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980–1994. *Circ J* 2006; **70**: 960–964. OS
- Kadota A, Hozawa A, Okamura T, Kadowaki T, Nakamura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H, NIPPON DATA Research Group. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA9, 1990–2000. *Diabetes Care* 2007; **30**: 1533–1538. OS
- Saito I, Konishi M, Watanabe K, Kondo H, Fujimotos K, Okada K. The metabolic syndrome and risk of stroke in a rural community in Japan. *Nippon Koshu Eisei Zasshi* 2007; **54**: 677–683. Japanese.
- Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H, The NIPPON DATA80 Research Group. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). *J Hypertens* 2006; **24**: 459–462. OS
- Murakami Y, Hozawa A, Okamura T, Ueshima H, Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Research Group (EPOCH-JAPAN). Relation of blood pressure and all-cause mortality in 180 000 Japanese participants: pooled analysis of 13 cohort studies. *Hypertension* 2008; **51**: 1483–1491. MA
- Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A, Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. *Hypertension* 2003; **42**: 69–75. OS
- Miura K, Soyama Y, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Yoshita K, Kagamimori S, Nakagawa H. Comparison of four blood pressure indexes for the prediction of 10-year stroke risk in middle-aged and older Asians. *Hypertension* 2004; **44**: 715–720. OS
- Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Kondo Y, Imai Y. Predicting stroke using 4 ambulatory blood pressure monitoring-derived blood pressure indices: the Ohasama Study. *Hypertension* 2006; **48**: 877–882. RT
- Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. *Stroke* 1995; **26**: 361–367. OS
- Kita Y, Okayama A, Ueshima H, Wada M, Nozaki A, Choudhury SR, Bonita R, Inamoto Y, Kasamatsu T. Stroke incidence and case fatality in Shiga, Japan 1989–1993. *Int J Epidemiol* 1999; **28**: 1059–1065.
- Kinjo K, Kimura Y, Shinzato Y, Tomori M, Komine Y, Kawazoe N, Takishita S, Fukiyama K and COSMO Group. An epidemiological analysis of cardiovascular diseases in Okinawa, Japan. *Hypertens Res* 1992; **15**: 111–119. OS
- Morikawa Y, Nakagawa H, Naruse Y, Nishijo M, Miura K, Tabata M, Hirokawa W, Kagamimori S, Honda M, Yoshita K, Hayashi K. Trends in stroke incidence and acute case fatality in a Japanese rural area: the Oyabe study. *Stroke* 2000; **31**: 1583–1587. OS
- Kiyohara Y, Kubo M, Kato I, Tanizaki Y, Tanaka K, Okubo K, Nakamura H, Iida M. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. *Stroke* 2003; **34**: 2343–2347. OS
- Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 h urinary sodium and potassium excretion. *BMJ* 1988; **297**: 319–328. OS
- Nakagawa H, Morikawa Y, Okayama A, Fujita Y, Yoshida Y, Mikawa K, Sakata K, Ishizaki M, Miura K, Naruse Y, Kagamimori S, Hashimoto T, Ueshima H. Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the Intersalt Study. *J Hum Hypertens* 1999; **13**: 735–741. OS
- Stamler J, Elliott P, Chan Q, INTERMAP Research Group. INTERMAP Appendix tables. *J Hum Hypertens* 2003; **17**: 665–775. OS
- The INTERSALT Co-operative Research Group. Appendix tables. Centre-specific results by age and sex. *J Hum Hypertens* 1989; **3**: 331–407. OS
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller III ER, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med* 2001; **344**: 3–10. RT
- Nakamura K, Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, Kita Y, Okayama A, Ueshima H, NIPPON DATA80, 90 Research Group. The proportion of

- individuals with obesity-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA80, 90. *Eur J Epidemiol* 2007; **22**: 691–698. OS
- 36 Tanaka T, Okamura T, Yamagata Z, Takebayashi T, Tamura U, Kusaka Y, Urano S, Miyoshi Y, Okayama A, Ueshima H, HIPOP-OHP Research Group. Awareness and treatment of hypertension and hypercholesterolemia in Japanese workers: the High-risk and Population Strategy for Occupational Health Promotion (HIPOP-OHP) study. *Hypertens Res* 2007; **30**: 921–928. OS
 - 37 Hozawa A, Ohkubo T, Kikuya M, Yamaguchi J, Ohmori K, Fujiwara T, Hashimoto J, Matsubara M, Kitaoka H, Nagai K, Tsuji I, Satoh H, Hisamichi S, Imai Y. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. *Hypertens Res* 2002; **25**: 57–63. OS
 - 38 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560–2572. GL
 - 39 Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. INTERSALT study findings. Public health and medical care implications. *Hypertension* 1989; **14**: 570–577. OS
 - 40 Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. *J Hum Hypertens* 2005; **19**: 801–807. OS
 - 41 Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ, Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension* 2005; **45**: 142–161. GL
 - 42 O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens* 2003; **21**: 821–848. GL
 - 43 Ménard J, Chatellier G, Day M, Vaur L. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. *J Hypertens Suppl* 1994; **12**: S21–S25. RT
 - 44 Oikawa T, Obara T, Ohkubo T, Kikuya M, Asayama K, Metoki H, Komai R, Murai K, Hashimoto J, Totsune K, Imai Y, J-HOME Study Group. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J-HOME study. *J Hypertens* 2006; **24**: 1737–1743. OS
 - 45 Fukunaga H, Ohkubo T, Kobayashi M, Tamaki Y, Kikuya M, Obara T, Nakagawa M, Hara A, Asayama K, Metoki H, Inoue R, Hashimoto J, Totsune K, Imai Y. Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. *J Hypertens* 2008; **26**: 685–690.
 - 46 Imai Y, Otsuka K, Kawano Y, Shimada K, Hayashi H, Tochikubo O, Miyakawa M, Fukiyama K, Japanese Society of Hypertension. Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home. *Hypertens Res* 2003; **26**: 771–782. GL
 - 47 Imai Y, Obara T, Ohkubo T. How many times should we ask subjects to measure blood pressure at home on each occasion? *J Hypertens* 2007; **25**: 1987–1991. GL
 - 48 Kawabe H, Saito I. Which measurement of home blood pressure should be used for clinical evaluation when multiple measurements are made? *J Hypertens* 2007; **25**: 1369–1374. OS
 - 49 Ohkubo T, Asayama K, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y, Ohasama Study. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. *J Hypertens* 2004; **22**: 1099–1104. OS
 - 50 Imai Y, Munakata M, Tsuji I, Ohkubo T, Satoh H, Yoshino H, Watanabe N, Nishiyama A, Onodera N, Kato J, Sekino M, Aihara A, Kasai Y, Abe K. Seasonal variation in blood pressure in normotensive women studied by home measurements. *Clin Sci (Lond)* 1996; **90**: 55–60. OS
 - 51 Kikuya M, Chonan K, Imai Y, Goto E, Ishii M, Research Group to Assess the Validity of Automated Blood Pressure Measurement Devices in Japan. Accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. *J Hypertens* 2002; **20**: 629–638. OS
 - 52 Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, Ito S, Satoh H, Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. *J Hypertens* 1998; **16**: 971–975. OS
 - 53 Segá R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. *Circulation* 2005; **111**: 1777–1783. OS
 - 54 Hozawa A, Ohkubo T, Nagai K, Kikuya M, Matsubara M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. *Arch Intern Med* 2000; **160**: 3301–3306. OS
 - 55 Asayama K, Ohkubo T, Kikuya M, Metoki H, Obara T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Use of 2003 European Society of Hypertension-European Society of Cardiology guidelines for predicting stroke using self-measured blood pressure at home: the Ohasama study. *Eur Heart J* 2005; **26**: 2026–2031. OS
 - 56 Asayama K, Ohkubo T, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: the Ohasama study. *Stroke* 2004; **35**: 2356–2361. OS
 - 57 Nishinaga M, Takata J, Okumiyu K, Matsubayashi K, Ozawa T, Doi Y. High morning home blood pressure is associated with a loss of functional independence in the community-dwelling elderly aged 75 years or older. *Hypertens Res* 2005; **28**: 657–663. OS
 - 58 Stergiou GS, Baibas NM, Kaloegeropoulos PG. Cardiovascular risk prediction based on home blood pressure measurement: the Didima study. *J Hypertens* 2007; **25**: 1590–1596. OS
 - 59 Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. *Kidney Int* 2006; **69**: 406–411. OS
 - 60 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997; **157**: 2413–2446. GL
 - 61 European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003; **21**: 1011–1053. GL
 - 62 Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. *J Hypertens* 1999; **17**: 151–183. GL
 - 63 Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N, Itoh O, Bando T, Sakuma M, Fukao A, Satoh H, Hisamichi S, Abe K. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. *Am J Hypertens* 1997; **10**: 409–418. OS
 - 64 Imai Y, Ohkubo T, Tsuji I, Nagai K, Satoh H, Hisamichi S, Abe K. Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. *Blood Press Monit* 1996; **1** (Suppl 2): S51–S58. OS
 - 65 Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). *Hypertens Res* 2006; **29** (Suppl): S1–S105. GL
 - 66 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Vigliani M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waebler B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. *J Hypertens* 2007; **25**: 1105–1187. GL
 - 67 Fujiwara T, Nishimura T, Ohkubo T, Imai Y, HOMED-BP Study Group. Rationale and design of HOMED-BP Study: hypertension objective treatment based on measurement by electrical devices of blood pressure study. *Blood Press Monit* 2002; **7**: 77–82. RT
 - 68 Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Sekino H, Nihei M, Yoshinaga K. Determination of clinical accuracy and nocturnal blood pressure pattern by new portable device for monitoring indirect ambulatory blood pressure. *Am J Hypertens* 1990; **3**: 293–301. OS
 - 69 Imai Y, Sasaki S, Minami N, Munakata M, Hashimoto J, Sakuma H, Sakuma M, Watanabe N, Imai K, Sekino H, Abe K. The accuracy and performance of the A&D TM 2421, a new ambulatory blood pressure monitoring device based on the cuff-oscillometric method and the Korotkoff sound technique. *Am J Hypertens* 1992; **5**: 719–726. OS
 - 70 Kuwajima I, Nishinaga M, Kanamaru A. The accuracy and clinical performance of a new compact ambulatory blood pressure monitoring device, the ES-H531. *Am J Hypertens* 1998; **11**: 1328–1333. OS
 - 71 Shimada K, Imai Y, Kuwajima I, Tochikubo O, Hayashi H, Kawano Y, Kawasaki K. [Guidelines for 24-h ambulatory blood pressure monitoring (ABPM)]. *Jpn Circ J* 2000; **64** (Suppl 5): 1207–1248. Japanese. GL
 - 72 Sokolow M, Wedegard D, Kain HK, Hinman AT. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. *Circulation* 1966; **34**: 279–298. OS
 - 73 Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B, SAMPLE Study Group. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. *Circulation* 1997; **95**: 1464–1470. OS
 - 74 Ohkubo T, Hozawa A, Nagai K, Kikuya M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood

- pressure measurements in a general population: the Ohasama study. *J Hypertens* 2000; **18**: 847–854. OS
- 75 Suzuki Y, Kuwajima I, Aono T, Kanemaru A, Nishinaga M, Shibata H, Ozawa T. Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-h blood pressure. *Hypertens Res* 2000; **23**: 323–330. OS
 - 76 Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA* 1999; **282**: 539–546. OS
 - 77 Agarwal R, Andersen MJ. Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. *Am J Nephrol* 2006; **26**: 503–510. OS
 - 78 Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension* 2005; **45**: 240–245. OS
 - 79 Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Reboldi G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. *Hypertension* 1994; **24**: 793–801. OS
 - 80 Kawasaki T, Uezono K. An attempt for establishment of standard values for circadian blood pressure on the basis of clinically healthy Japanese. In: Omae T, Kawasaki T (eds). *Clinical Practice of Blood Pressure Monitoring*. Igaku-Shoin Ltd: Tokyo, 1993, pp 181–189 (in Japanese). GL
 - 81 Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA, International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation* 2007; **115**: 2145–2152. OS
 - 82 Kikuya M, Hozawa A, Ohkubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension* 2000; **36**: 901–906. OS
 - 83 Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Tsuji I, Imai Y. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. *Arch Intern Med* 2005; **165**: 1541–1546. OS
 - 84 Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension* 2005; **45**: 203–208. OS
 - 85 Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Satoh H, Hisamichi S. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. *Am J Hypertens* 1997; **10**: 1201–1207. CT
 - 86 Kario K, Pickering TG, Umeda Y, Hoshida S, Hoshida Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003; **107**: 1401–1406. OS
 - 87 Chonan K, Hashimoto J, Ohkubo T, Tsuji I, Nagai K, Kikuya M, Hozawa A, Matsubara M, Suzuki M, Fujiwara T, Araki T, Satoh H, Hisamichi S, Imai Y. Insufficient duration of action of antihypertensive drugs mediates high blood pressure in the morning in hypertensive population: the Ohasama study. *Clin Exp Hypertens* 2002; **24**: 261–275. OS
 - 88 Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004; **291**: 1342–1349. OS
 - 89 Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of 'masked' hypertension and 'white-coat' hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol* 2005; **46**: 508–515. OS
 - 90 Harada K, Karube Y, Saruhara H, Takeda K, Kuwajima I. Workplace hypertension is associated with obesity and family history of hypertension. *Hypertens Res* 2006; **29**: 969–976. OS
 - 91 Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. *Hypertension* 2006; **47**: 149–154. OS
 - 92 Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. *Diabetes Care* 2002; **25**: 2218–2223. OS
 - 93 Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, Hara A, Hirose T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Prediction of stroke by home 'morning' versus 'evening' blood pressure values: the Ohasama study. *Hypertension* 2006; **48**: 737–743. OS
 - 94 Kario K, Ishikawa J, Pickering TG, Hoshida S, Eguchi K, Morinari M, Hoshida Y, Kuroda T, Shimada K. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. *Hypertens Res* 2006; **29**: 581–587. OS
 - 95 Chonan K, Kikuya M, Araki T, Fujiwara T, Suzuki M, Michimata M, Hashimoto J, Ohkubo T, Hozawa A, Yamamoto N, Miyawaki Y, Matsubara M, Imai Y. Device for the self-measurement of blood pressure that can monitor blood pressure during sleep. *Blood Press Monit* 2001; **6**: 203–205. OS
 - 96 Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. *Hypertension* 1990; **16**: 692–699. OS
 - 97 Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. *Circulation* 1990; **81**: 528–536. OS
 - 98 Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. *Am J Hypertens* 1994; **7**: 23–29. OS
 - 99 Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. *J Hypertens* 2002; **20**: 2183–2189. OS
 - 100 Shimada K, Imai Y, Kuwajima I, Abe K. Patients characteristics and effects of the long-term acting calcium channel blocker barnidipine on circadian blood pressure changes: results of the Japanese Multicenter Study on Barnidipine with Ambulatory Blood Pressure Monitoring. *Blood Press Monit* 2001; **6**: S25–S30. OS
 - 101 Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. *Hypertension* 1996; **27**: 130–135. OS
 - 102 Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA, International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. *Lancet* 2007; **370**: 1219–1229. MA
 - 103 Kelly R, Fitchett D. Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique. *J Am Coll Cardiol* 1992; **20**: 952–963. OS
 - 104 Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension* 2001; **38**: 932–937. OS
 - 105 Pauca AL, Kon ND, O'Rourke MF. The second peak of the radial artery pressure wave represents aortic systolic pressure in hypertensive and elderly patients. *Br J Anaesth* 2004; **92**: 651–657. OS
 - 106 Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; **113**: 1213–1225. RT
 - 107 Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, Wang JG, Wilkinson IB, Williams B, Vlachopoulos C. Central blood pressure measurements and antihypertensive therapy: a consensus document. *Hypertension* 2007; **50**: 154–160. GL
 - 108 Hashimoto J, Imai Y, O'Rourke MF. Monitoring of antihypertensive therapy for reduction in left ventricular mass. *Am J Hypertens* 2007; **20**: 1229–1233. CT
 - 109 Ueda K, Omae T, Hasuo Y, Kiyohara Y, Fujii I, Wada J, Kato I, Kawano H, Shinkawa A, Omura T, Fujishima M. Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-term prospective study. *J Hypertens* 1988; **6**: 991–997. OS
 - 110 Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. *Circulation* 1999; **100**: 354–360. OS
 - 111 Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. *Am Heart J* 1987; **113**: 1489–1494. OS
 - 112 Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A, European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. *J Hypertens* 2006; **24**: 603–610. GL
 - 113 Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O'Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. *Arch Intern Med* 2002; **162**: 2313–2321. OS
 - 114 Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, Metoki H, Ohmori K, Hoshi H, Hashimoto J, Satoh H, Tsuji I, Imai Y. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. *Am J Hypertens* 2004; **17**: 1005–1010. OS
 - 115 Benetos A, Zureik M, Morcet J, Thomas F, Bean K, Safar M, Ducimetière P, Guize L. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. *J Am Coll Cardiol* 2000; **35**: 673–680. OS
 - 116 Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekblom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000; **355**: 865–872. MA

- 117 Darne B, Girend X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. *Hypertension* 1989; **13**: 392–400. OS
- 118 Benetos A, Safar M, Rudnicki A, Smulyan H, Richard JL, Ducimetière P, Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. *Hypertension* 1997; **30**: 1410–1415. OS
- 119 Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 2003; **21**: 1983–1992. GL
- 120 Shimamoto K. New trends in management and treatment of hypertension (JNC-VI and the current status in Japan). *Nippon Naika Gakkai Zasshi* 1999; **88**: 401–405. Japanese. RV
- 121 MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; **335**: 765–774. MA
- 122 Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001; **345**: 1291–1297. OS
- 123 Shimamoto K, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Itakura H, J-LIT Study Group. The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study. *Hypertens Res* 2005; **28**: 879–887. CT
- 124 Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. *Lancet* 2001; **358**: 1682–1686. OS
- 125 Kassai B, Gueyffier F, Boissel JP, Bouitrie F, Cucherat M. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? *J Clin Epidemiol* 2003; **56**: 977–982.
- 126 Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. [Definition and the diagnostic standard for metabolic syndrome]. *Nippon Naika Gakkai Zasshi*. 2005; **94**: 794–809. Japanese. GL
- 127 National Kidney Foundation. Executive summary. *Am J Kidney Dis* 2004; **43**: s16–s33. GL
- 128 Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 2005; **112**: 969–975. OS
- 129 Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. *J Hypertens* 2004; **22**: 1635–1639. RV
- 130 Rahman M, Pressel S, Davis BR, Rahman M, Pressel S, Davis BR, Nwachuku C, Wright Jr JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. *Ann Intern Med* 2006; **144**: 172–180. OS
- 131 Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsum K, Hoshi H, Ito S, Imai Y. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. *Nephrol Dial Transplant* 2007; **22**: 1910–1915. OS
- 132 Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int* 2006; **69**: 1264–1271. OS
- 133 de Leeuw PW, Ruilope LM, Palmer CR, de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancina G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. *Arch Intern Med* 2004; **164**: 2459–2464. RT
- 134 Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005; **165**: 1410–1419. MA
- 135 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; **358**: 1033–1041. RT
- 136 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; **317**: 703–713. RT
- 137 Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. *Diabetes* 1996; **45**: S14–S16. OS
- 138 An overview of dialysis treatment in Japan (as of Dec 31, 2006). *J Jpn Soc Dial Ther* 2008; **41**: 1–28.
- 139 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998; **351**: 1755–1762. RT
- 140 Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; **345**: 861–869. RT
- 141 Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 2002; **61**: 1086–1097. RT
- 142 Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. *Kidney Int Suppl* 1996; **55**: S57–S62. CT
- 143 Asayama K, Ohkubo T, Satoh A, Hara A, Obara T, Yasui D, Metoki H, Inoue R, Kikuya M, Hashimoto J, Hoshi H, Satoh H, Imai Y. Proposal of a riskstratification system for the Japanese population based on blood pressure levels: the Ohasama Study. *Hypertens Res* 2008; **31**: 1315–1322. OS
- 144 Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Piorri S, Ostergren J, Tuomilehto J, Thraivsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Piorri SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Scherthaner G, Volpe M, Wood D, Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007; **28**: 88–136. GL
- 145 Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama S, Yamanishi H, Matsumoto M, Hori M. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. *Circulation* 2001; **104**: 63–67. CT
- 146 Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. *Hypertens Res* 2007; **30**: 1177–1185. CT
- 147 Ishikawa J, Tamura Y, Hoshida S, Eguchi K, Ishikawa S, Shimada K, Kario K. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. *Stroke* 2007; **38**: 911–917. RT
- 148 Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke* 1997; **28**: 1932–1939.
- 149 Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol* 2001; **38**: 238–245. OS
- 150 Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. *Stroke* 2003; **34**: 1126–1129. OS
- 151 Naka H, Nomura E, Takahashi T, Wakabayashi S, Mimori Y, Kajikawa H, Kohriyama T, Matsumoto M. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *AJNR Am J Neuroradiol* 2006; **27**: 830–835. OS
- 152 Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B, International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. *Lancet* 2006; **367**: 1262–1270. RV
- 153 Cooper LS, Wong TY, Klein R, Cooper LS, Wong TY, Klein R, Sharrett AR, Bryan RN, Hubbard LD, Couper DJ, Heiss G, Sorlie P. Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. *Stroke* 2006; **37**: 82–86. OS
- 154 Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the electrocardiographic strain pattern in patients with resistant hypertension. *Hypertension* 2006; **48**: 437–442.
- 155 Okin PM, Devereux RB, Jern S, Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. *JAMA* 2004; **292**: 2343–2349. OS
- 156 Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. *Circulation* 2008; **117**: 1255–1260. OS
- 157 Muesan ML, Salvetti M, Monteduro C, Bonzi B, Painsi A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. *Hypertension* 2004; **43**: 731–738. OS
- 158 Eguchi K, Kario K, Hoshida S, Ishikawa J, Morinari M, Shimada K. Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients. *Am J Hypertens* 2005; **18**: 23–29. OS
- 159 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. *Nature* 1988; **332**: 78–81. OS
- 160 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasike BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ,

- Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 2003; **108**: 2154–2169. GL
- 161 Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. *Kidney Int* 2003; **63**: 1468–1474.
- 162 Matsuo S, Imai E, Horio Y, Yosuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, on behalf of the collaborators for developing Japanese equation for estimating GFR. The Japanese equations for estimating glomerular filtration rate from serum creatinine (Submitted, unpublished) OS.
- 163 Gerber LM, Schwartz JE, Pickering TG. Albumin-to-creatinine ratio predicts change in ambulatory blood pressure in normotensive persons: a 7.5-year prospective study. *Am J Hypertens* 2006; **19**: 220–226. OS
- 164 Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension* 2005; **45**: 198–202. OS
- 165 The Joint Committee of 'The Japan Academy of Neurosonology' and 'The Japan Society of Embolus Detection and Treatment' on Guideline for Neurosonology (Carotid Ultrasound Examination). *Neurosonology* 2006; **19**: 50. Japanese. GL
- 166 Nagai Y, Matsumoto M, Metter EJ. The carotid artery as a noninvasive window for cardiovascular risk in apparently healthy individuals. *Ultrasound Med Biol* 2002; **28**: 1231–1238. RV
- 167 Takiuchi S, Rakugi H, Honda K, Masuyama T, Hirata N, Ito H, Sugimoto K, Yanagitani Y, Moriuchi K, Okamura A, Higaki J, Ogihara T. Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. *Circulation* 2000; **102**: 766–770.
- 168 Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW, Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med* 2003; **163**: 1939–1942. OS
- 169 Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens Res* 2002; **25**: 359–364.
- 170 Tomiyama H, Hashimoto H, Hirayama Y, Yambe M, Yamada J, Koji Y, Shiina K, Yamamoto Y, Yamashina A. Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. *Hypertension* 2006; **47**: 180–188.
- 171 Munakata M, Nunokawa T, Yoshinaga K, Toyota T, J-TOPP Study Group. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension—a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). *Hypertens Res* 2006; **29**: 515–521. OS
- 172 Yambe M, Tomiyama H, Yamada J, Koji Y, Motobe K, Shiina K, Yamamoto Y, Yamashina A. Arterial stiffness and progression to hypertension in Japanese male subjects with high normal blood pressure. *J Hypertens* 2007; **25**: 87–93. OS
- 173 Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. *Hypertens Res* 2007; **30**: 219–228. CT
- 174 Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, Heiss G. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. *Circulation* 2006; **114**: 630–636. OS
- 175 Kario K, Eguchi K, Hoshide S, Hoshide Y, Umeda Y, Mitsuhashi T, Shimada K. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. *J Am Coll Cardiol* 2002; **40**: 133–141. OS
- 176 Kario K, Shimada K, Pickering TG. Abnormal nocturnal blood pressure falls in elderly hypertension: clinical significance and determinants. *J Cardiovasc Pharmacol* 2003; **41** (Suppl 1): S61–S66. OS
- 177 Kohara K, Tabara Y, Yamamoto Y, Miki T. Orthostatic hypertension: another orthostatic disorder to be aware of. *J Am Geriatr Soc* 2000; **48**: 1538–1539.
- 178 Lever AF, Ramsay LE. Treatment of hypertension in the elderly. *J Hypertens* 1995; **13**: 571–579. OS
- 179 Whelton PK, He J. Blood pressure reduction. In: Hennekens CH (ed). *Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease*. WB Saunders Co.: Philadelphia, 1999, pp 341–359.
- 180 Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekblom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E, The INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. *Ann Intern Med* 1997; **126**: 761–767. MA
- 181 MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. *Clin Exp Hypertens* 1993; **15**: 967–978. MA
- 182 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008; **358**: 1887–1898. RT
- 183 Takagi S, Saitoh S, Nakano M, Hayashi Y, Obara F, Onishi H, Shimamoto K. Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. *J Hypertens* 2000; **18**: 139–144. OS
- 184 Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens* 2005; **23**: 2157–2172. RT
- 185 Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B, PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. *J Hypertens* 2006; **24**: 1201–1208. OS
- 186 Fox KM, EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003; **362**: 782–788. RT
- 187 Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens* 2005; **23**: 641–648. CT
- 188 Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA* 2004; **292**: 2217–2225. RT
- 189 Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N, DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med* 1997; **336**: 1117–1124. RT
- 190 Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger Jr WH, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA, TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). *JAMA* 1998; **279**: 839–846. RT
- 191 Hayashi T, Tsumura K, Suematsu C, Okada K, Fujii S, Endo G. Walking to work and the risk for hypertension in men: the Osaka Health Survey. *Ann Intern Med* 1999; **131**: 21–26. OS
- 192 Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R and Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. *JAMA* 1993; **270**: 713–724. RT
- 193 Singer DR, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. *Hypertension* 1995; **25**: 1042–1044. RT
- 194 Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N, Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. *Lancet* 2007; **369**: 1431–1439. RT
- 195 Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. *Hypertension* 2008; **51**: 393–398. RT
- 196 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet* 2002; **359**: 995–1003. RT
- 197 Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2006; **366**: 895–906. RT
- 198 Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; **363**: 2022–2031. RT
- 199 Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. *Lancet* 2004; **363**: 2049–2051. CT
- 200 Wing LM, Brown MA, Beilin LJ, Ryan P, Reid CM, ANBP2 Management Committee and Investigators. Second Australian National Blood Pressure Study. 'Reverse white-coat hypertension' in older hypertensives. *J Hypertens* 2002; **20**: 639–644. OS
- 201 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007; **369**: 201–207. MA
- 202 Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. *Hypertens Res* 2003; **26**: 159–162. CT
- 203 Yoshida K, Matsuo H, Omae T, Fujii J. Patient-hospital relationship and quality of life in elderly patients with hypertension. *Hypertens Res* 1995; **18**: 77–83. OS
- 204 Kaplan NM. Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. *Arch Intern Med* 1997; **157**: 945–948.

- 205 Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzuza-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Horteiga study. *J Hypertens* 2003; **21**: 1283–1289. OS
- 206 Dimenäs ES, Wiklund IK, Dahlöf CG, Lindvall KG, Olofsson BK, De Faire UH. Differences in the subjective well-being and symptoms of normotensives, borderline hypertensives and hypertensives. *J Hypertens* 1989; **7**: 885–890.
- 207 Mikami H, Ogihara T. Quality of life in the pharmacologically treated elderly patients. *Nippon Ronen Igakkai Zasshi* 1999; **36**: 186–190. Japanese.
- 208 Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH. The effects of antihypertensive therapy on the quality of life. *N Engl J Med* 1986; **314**: 1657–1664. RT
- 209 Grimm Jr RH, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, Prineas RJ, Liebson PR. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. *Arch Intern Med* 1997; **157**: 638–648. RT
- 210 Degl'Innocenti A, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A, Wiklund I. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). *J Hum Hypertens* 2004; **18**: 239–245. RT
- 211 Bane C, Hughes CM, Cupples ME, McElnay JC. The journey to concordance for patients with hypertension: a qualitative study in primary care. *Pharm World Sci* 2007; **29**: 534–540.
- 212 Saito I. Gap between untreated, treated patients' and physicians' attitudes and awareness toward hypertension and its complications, cardiovascular diseases. *Prog Med* 2008; **28**: 1215–1222. Japanese.
- 213 Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, Wallston KA, Dittus RS, Alvarez V, Cobb J, Speroff T. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. *Ann Intern Med* 2006; **145**: 165–175. RT
- 214 Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. *JAMA* 2006; **296**: 2563–2571. RT
- 215 Saito I. Medication compliance and blood pressure control: the effect of number of antihypertensive drugs on medication compliance. *Ketsuatsu* 2006; **13**: 1019–1025. Japanese.
- 216 Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. *Arch Intern Med* 2004; **164**: 722–732. RV
- 217 Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007; **120**: 713–719. MA
- 218 Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B, LIFE Study Group. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. *J Hypertens* 2005; **23**: 1425–1431. OS
- 219 Saito I, Fujikawa K, Saruta T, ADVANCE-Combi Study Group. Cost-effectiveness analysis: controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. *Hypertens Res* 2008; **31**: 1399–1405. OS
- 220 Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2006; **166**: 2191–2201. RT
- 221 Saito I, Kobatashi M, Saruta T. Economic analysis of antihypertensive agents in treating patients with essential hypertension. *Rinsho Iyaku* 2003; **19**: 777–788. Japanese.
- 222 Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Gen Intern Med* 2008; **23**: 509–516. RT
- 223 Saito I, Kobayashi M, Matsushita Y, Saruta T. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. *Jpn Med Assoc J* 2005; **48**: 574–585.
- 224 Kawano Y, Ando K, Matsuura H, Tsuchihashi T, Fujita T, Ueshima H, Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) rationale for salt restriction and salt-restriction target level for the management of hypertension. *Hypertens Res* 2007; **30**: 879–886. GL
- 225 He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens* 2002; **16**: 761–770. MA
- 226 The working group for dietary salt reduction of the Japanese Society of Hypertension. Low-salt (6g/day) diet recipe for the patients with hypertension. Japanese Society of Hypertension: Tokyo, 2006. GL
- 227 Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J, American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation* 2006; **114**: 82–96. GL
- 228 Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension* 2006; **47**: 296–308. GL
- 229 Ohta Y, Tsuchihashi T, Ueno M, Kajioaka T, Onaka U, Tominaga M, Eto K. Relationship between the awareness of salt restriction and the actual salt intake in hypertensive patients. *Hypertens Res* 2004; **27**: 243–246.
- 230 Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ* 2007; **334**: 885. MA
- 231 Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H, Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) assessment of salt intake in the management of hypertension. *Hypertens Res* 2007; **30**: 887–893.
- 232 Geleijnse JM, Hofman A, Witteman JC, Hazebroek AA, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction on blood pressure. *Hypertension* 1997; **29**: 913–917. RT
- 233 Japanese Food Guide Spinning Top. *Decided by Ministry of Health, Labour and Welfare and Ministry of Agriculture, Forestry and Fisheries*. Dai-ichi Shuppan Publishing: Tokyo, 2005. GL
- 234 Azadbakht L, Mirmiran P, Esmailzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* 2005; **28**: 2823–2831. RT
- 235 Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, Daviglus ML, He K, Moag-Stahlberg A, Rodriguez BL, Steffen LM, Van Horn L, Yarnell J, Zhou B, INTERMAP Research Group. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. *Hypertension* 2007; **50**: 313–319. OS
- 236 Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. *J Hypertens* 2002; **20**: 1493–1499. MA
- 237 Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S, JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. *Circulation* 2006; **113**: 195–202. OS
- 238 Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino Sr RB, O'Donnell CJ. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation* 2007; **116**: 39–48. OS
- 239 Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003; **42**: 878–884. MA
- 240 Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006; **24**: 215–233. MA
- 241 Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A, American College of Sports Medicine, American Heart Association. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation* 2007; **116**: 1081–1093. GL
- 242 Tashiro E, Miura S, Koga M, Sasaguri M, Ideishi M, Ikeda M, Tanaka H, Shindo M, Arakawa K. Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. *Clin Exp Pharmacol Physiol* 1993; **20**: 689–696. RT
- 243 Shaper AG, Wannamethee G, Walker M. Physical activity, hypertension and risk of heart attack in men without evidence of ischaemic heart disease. *J Hum Hypertens* 1994; **8**: 3–10.
- 244 Ohkubo T, Hozawa A, Nagatomi R, Fujita K, Sauvaget C, Watanabe Y, Anzai Y, Tamagawa A, Tsuji I, Imai Y, Ohmori H, Hisamichi S. Effects of exercise training on home blood pressure values in older adults: a randomized controlled trial. *J Hypertens* 2001; **19**: 1045–1052. RT
- 245 Nakamura K, Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, Kita Y, Okayama A, Ueshima H, NIPPON DATA90 Research Group. The proportion of individuals with alcohol-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA90. *Hypertens Res* 2007; **30**: 663–668. OS
- 246 Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. *Circulation* 2007; **116**: 1306–1317. RV
- 247 Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2001; **38**: 1112–1117. MA
- 248 Gropelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. *J Hypertens* 1992; **10**: 495–499.
- 249 Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. *Hypertension* 1999; **33**: 586–590. RT
- 250 Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. *Hypertens Res* 2007; **30**: 479–488. RV
- 251 Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. *Intern Med* 2006; **45**: 1039–1043. OS

- 252 The Eurowinter Group. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. *Lancet* 1997; **349**: 1341–1346. OS
- 253 Espeland MA, Whelton PK, Kostis JB, Bahnson JL, Ettinger WH, Cutler JA, Appel LJ, Kumanyika S, Farmer D, Elam J, Wilson AC, Applegate WB, TONE Cooperative Research Group. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. Trial of Nonpharmacologic Interventions in the Elderly. *Arch Fam Med* 8: 228–236. RT
- 254 Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR, Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA* 289: 2083–2093. RT
- 255 Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003; **362**: 1527–1535. MA
- 256 Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *J Hypertens* 2007; **25**: 951–958. MA
- 257 William B, Poulter NR, Brown MJ. British Hypertension Society. British Hypertension Society guidelines (BHS-IV). *J Fam Pract* 2004; **53**: 528–550. GL
- 258 Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. *Am J Hypertens* 2001; **14**: 241–247. RV
- 259 Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; **354**: 1751–1756. RT
- 260 Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Takahashi H, Hashimoto J, Totsune K, Imai Y, J-HOME Study Group. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. *Hypertens Res* 2004; **27**: 755–763. OS
- 261 Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents—a preliminary report. *Hypertension* 2007; **49**: 272–275. RT
- 262 Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ* 2003; **326**: 1427. MA
- 263 Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Fontao MJ, Soler R, Fernández JR. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. *Hypertension* 2005; **46**: 1053–1059.
- 264 Elliott WJ. Drug interactions and drugs that affect blood pressure. *J Clin Hypertens (Greenwich)* 2006; **8**: 731–737. RV
- 265 Sugiyama T, Kiraku J, Ashida T, Fujii J. Remission of hypertension: retrospective observations over a period of 20 years. *Hypertens Res* 1998; **21**: 103–108.
- 266 Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, Schuurman FH, Meyboom-de Jong B, Crijns HJ. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. *J Hypertens* 2001; **19**: 303–309. RT
- 267 Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. *J Am Coll Cardiol* 2006; **48**: 833–838. CT
- 268 Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. *Kidney Int* 2007; **72**: 1543–1549. RT
- 269 Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. *Hypertens Res* 2007; **30**: 621–626. RT
- 270 Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. *Am J Med Sci* 2007; **333**: 321–326. RT
- 271 Ohishi M, Takagi T, Ito N, Terai M, Tataru Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. *Hypertens Res* 2007; **30**: 797–806. CT
- 272 Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamoto T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. *Nat Cell Biol* 2004; **6**: 499–506.
- 273 Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008; **358**: 1547–1559. RT
- 274 Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; **359**: 1004–1010. RT
- 275 Arai T, Sekizawa K, Ohnri T, Fujiwara H, Yoshimi N, Matsuoka H, Sasaki H. ACE inhibitors and protection against pneumonia in elderly patients with stroke. *Neurology* 2005; **64**: 573–574. OS
- 276 National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. *Hypertension* 1999; **34**: 1129–1133. RT
- 277 Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA* 1998; **279**: 1903–1907. MA
- 278 Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and anti-hypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. *N Engl J Med* 2000; **342**: 905–912. OS
- 279 Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright Jr JT, Oakes R, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; **292**: 2227–2236. RT
- 280 Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. *Int J Clin Pract* 2005; **59**: 562–570. RV
- 281 Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol* 2003; **41**: 1148–1155. RT
- 282 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999; **341**: 709–717. RT
- 283 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; **348**: 1309–1321. RT
- 284 Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. *Hypertension* 2007; **49**: 839–845. RT
- 285 Hasebe N, Kikuchi K, NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. *J Hypertens* 2005; **23**: 445–453. RT
- 286 Saito I, Saruta T, ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. *Hypertens Res* 2006; **29**: 789–796. RT
- 287 Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA* 2003; **290**: 2805–2816. RT
- 288 Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarsen A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S, A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet* 364: 849–857. RT
- 289 Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. *Hypertens Res* 2007; **30**: 301–306. CT
- 290 Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007; **370**: 829–840. RT
- 291 Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. *Am J Hypertens* 2004; **17**: 793–801. RT
- 292 Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. *N Engl J Med* 2006; **355**: 385–392. RV
- 293 Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. *J Hypertens* 2001; **19**: 2063–2070. OS
- 294 Kaplan NM. Treatment of hypertension. In: *Kaplan's Clinical Hypertension*, 9th edn. Lippincott Williams & Wilkins: Philadelphia, 2006, pp 217–310.

- 295 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; **288**: 2981–2997. RT
- 296 Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm Jr RH, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ, CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA* 2009; **207**: 2073–2082. RT
- 297 Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000; **356**: 366–372. RT
- 298 Ogihara T, Nakao K, Fukui T, Fukuyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T, CASE-J Trial Group. Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. The optimal target blood pressure for antihypertensive treatment in the Japanese elderly patients with high-risk hypertension: a subanalysis of CASE-J trial. *Hypertens Res* 2008; **31**: 1595–1601. RT
- 299 Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Hashimoto J, Totsumi K, Imai Y. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. *J Hypertens* 2005; **23**: 1653–1660. OS
- 300 Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. *Hypertens Res* 2006; **29**: 143–151. CT
- 301 Ohta Y, Tsuchihashi T, Fujii K, Matsumura K, Ohya Y, Uezono K, Abe I, Iida M. Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study. *J Hum Hypertens* 2004; **18**: 273–278. OS
- 302 Ono A, Fujita T. Factors relating to inadequate control of blood pressure in hypertensive outpatients. *Hypertens Res* 2003; **26**: 219–224. OS
- 303 Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. *Am J Hypertens* 2003; **16**: 925–930. CT
- 304 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research. *Hypertension* 2008; **51**: 1403–1419. GL
- 305 Broderick JP, Adams HP, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, Tilley B, Zabramski JM, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1999; **30**: 905–915. GL
- 306 Adams Jr HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1994; **25**: 1901–1914. GL
- 307 Bath P, Chalmers J, Powers W, Beilin L, Davis S, Lenfant C, Mancia G, Neal B, Whitworth J, Zanchetti A, International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. *J Hypertens* 2003; **21**: 665–672. GL
- 308 Osaki Y, Matsubayashi K, Yamasaki M, Okumura K, Yoshimura K, Yoshimura K, Hamashige N, Doi Y. Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. *Hypertens Res* 1998; **21**: 169–173. CT
- 309 Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberating altering blood pressure in acute stroke. The Cochrane Library, Issue 3, 2003. Update Software, Oxford, 2003.
- 310 The National Institute of Neurological Disorders and Stroke: Proceedings of national symposium on rapid identification and treatment of acute stroke. NIH publication 1997; No 97-4239: 1–183.
- 311 Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijndicks EF, American Heart Association. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke* 2007; **38**: 1655–1711. GL
- 312 Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiani P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. *Stroke* 2003; **34**: 1699–1703. RT
- 313 Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M, American Heart Association. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. *Stroke* 2007; **38**: 2001–2023. GL
- 314 Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J, INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. *Lancet Neurol* 2008; **7**: 391–399. RT
- 315 Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. *Stroke* 1993; **24**: 1844–1849.
- 316 The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. *Stroke* 1993; **24**: 543–548. RT
- 317 PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)* 1995; **108**: 710–717. RT
- 318 Eriksson S, Olofsson B-V, Wester P-O. Atenolol in secondary prevention after stroke. *Cerebrovasc Dis* 1995; **5**: 21–25.
- 319 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000; **342**: 145–153. RT
- 320 Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiani P, Diener HC, MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke* 2005; **36**: 1218–1226. RT
- 321 Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke* 2003; **34**: 2741–2748. MA
- 322 Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu Y, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med* 2008; **359**: 1225–1237. RT
- 323 Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T, American Heart Association. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006; **37**: 577–617. GL
- 324 Rothwell PM, Howard SC, Spence JD, Carotid Endarterectomy Trialists' Collaboration. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. *Stroke* 2003; **34**: 2583–2590. MA
- 325 Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M, Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. *Circulation* 2007; **115**: 2969–2975. RT
- 326 Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. *Stroke* 1998; **29**: 1806–1809. OS
- 327 Japanese Society for Detection of Asymptomatic Brain Diseases. Guidelines for Detection of Asymptomatic Brain Diseases 2003. (internet) <http://www.snh.or.jp/jsbd/pdf/guideline2003.pdf>. GL
- 328 The Joint Committee on Guidelines for the Management of Stroke. Japanese Guidelines for the Management of Stroke (in Japanese). Kyowa Kikaku: Tokyo, 2004. GL
- 329 Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med* 2003; **348**: 1215–1222. OS
- 330 Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J. Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. *Stroke* 2000; **31**: 1646–1650. CT
- 331 Kato H, Izumiya M, Izumiya K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. *Stroke* 2002; **33**: 1536–1540. CT
- 332 Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. *Cerebrovasc Dis* 2003; **16**: 280–285.
- 333 Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J, PROGRESS CT Substudy Investigators. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. *Hypertens Res* 2004; **27**: 147–156. RT
- 334 Yamamoto Y, Akiyuchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. *Stroke* 1998; **29**: 570–576. OS
- 335 Kario K, Pickering TG, Matsuo T, Hoshida S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. *Hypertension* 2001; **38**: 852–857. OS
- 336 Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. *Lancet* 2001; **358**: 1305–1315. MA
- 337 Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. *Arch Intern Med* 1991; **151**: 1277–1279. MA
- 338 Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W, PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000; **102**: 1503–1510. RT

- 339 Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. *Am Heart J* 2003; **146**: E20. RT
- 340 Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsue K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIB-B) randomized trial. *Hypertens Res* 2004; **27**: 181–191. RT
- 341 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996; **335**: 1001–1009. RT
- 342 Messerli FH, Mancina G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med* 2006; **144**: 884–893. OS
- 343 Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antedecent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. *Hypertension* 2008; **51**: 48–54. OS
- 344 Bradley HA, Wiyongse CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. *J Hypertens* 2006; **24**: 2131–2141. MA
- 345 Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol* 2007; **50**: 563–572. RV
- 346 Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. *N Engl J Med* 1985; **313**: 1055–1058. RT
- 347 Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001; **357**: 1385–1390. RT
- 348 The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1988; **319**: 385–392. RT
- 349 Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. *Am J Cardiol* 2004; **93**: 969–973. RT
- 350 Yui Y, Shinoda E, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases B (JMIB-B) Study Group. Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIB-B substudy). *J Hypertens* 2007; **25**: 2019–2026. RT
- 351 Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu M, Kimura A, Yamamoto K, Yabushita H, Katori R. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. *Circulation* 1997; **95**: 2368–2373. CT
- 352 Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. *N Engl J Med* 1992; **327**: 669–677. RT
- 353 Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003; **349**: 1893–1906. RT
- 354 Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, JCARE-GENERAL Investigators. Characteristics and outcomes of patients with heart failure in general practices and hospitals. *Circ J* 2007; **71**: 449–454. OS
- 355 Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 1970; **213**: 1143–1152. RT
- 356 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991; **325**: 293–302. RT
- 357 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; **327**: 685–691. RT
- 358 Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001; **345**: 1667–1675. RT
- 359 Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003; **362**: 759–766. RT
- 360 Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; **362**: 772–776. RT
- 361 Yusuf S, Pfeffer MA, Swedberg K, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; **362**: 777–781. RT
- 362 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; **334**: 1349–1355. RT
- 363 Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, János A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P, MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). *JAMA* 2000; **283**: 1295–1302. RT
- 364 CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; **353**: 9–13. RT
- 365 Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacs P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; **344**: 1651–1658. RT
- 366 Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith Jr SC. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. *Circulation* 2001; **104**: 2996–3007. GL
- 367 Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberger GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996; **335**: 1107–1114. RT
- 368 Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990; **322**: 1561–1566. OS
- 369 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation* 1997; **97**: 48–54. OS
- 370 Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. *Circulation* 2007; **116**: 700–705. RT
- 371 Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *Am J Med* 2003; **115**: 41–46. MA
- 372 Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. *Hypertens Res* 2002; **25**: 837–842. RT
- 373 Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. *Circ J* 2006; **70**: 995–1000. RT
- 374 Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. *Circulation* 1997; **95**: 2007–2014. RT
- 375 Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995; **98**: 476–484. OS
- 376 Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002; **113**: 359–364. OS
- 377 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998; **82**: 2N–9N. OS
- 378 Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA* 2006; **296**: 1242–1248. OS

- 379 Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC. RACE Investigators. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. *Eur Heart J* 2007; **28**: 741–751. RT
- 380 Lip GY, Frison L, Grind M, SPORTIF Investigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J* 2007; **28**: 752–759. OS
- 381 Wachtell K, Lehto M, Gerds E, Olsen MH, Horneštam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol* 2005; **45**: 712–719. RT
- 382 Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. *Am Heart J* 2006; **152**: 217–222. MA
- 383 Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol* 2005; **45**: 1832–1839. MA
- 384 Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, Miyauchi Y, Ohara T, Yashima M, Takano T. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. *Circ J* 2005; **69**: 671–676. OS
- 385 Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. *Hypertens Res* 2007; **30**: 535–540. OS
- 386 Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10 year follow-up study. *Hypertens Res* 2008; **31**: 433–441.
- 387 Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis* 2000; **36**: 646–661. GL
- 388 Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. *N Engl J Med* 1996; **334**: 13–18. OS
- 389 Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. *Hypertension* 2003; **41**: 1341–1345. OS
- 390 The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997; **349**: 1857–1863. RT
- 391 de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int* 2004; **65**: 2309–2320. RT
- 392 Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int* 2003; **63**: 1499–1507. OS
- 393 Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004; **164**: 659–663. OS
- 394 Go AS, Chertow GM, Fan D, McCulloch K, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; **351**: 1296–1305. OS
- 395 Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003; **139**: 137–147. GL
- 396 Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. *J Am Coll Cardiol* 2003; **41**: 47–55. OS
- 397 Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 2000; **102**: 203–210. RT
- 398 Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 2004; **351**: 1285–1295. RT
- 399 Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med* 2001; **134**: 629–636. CT
- 400 Rulpoel LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. *J Am Soc Nephrol* 2001; **12**: 218–225. RT
- 401 Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int* 2003; **63**: 1121–1129. OS
- 402 Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, Salem DN, Levey AS, Sarnak MJ. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. *Am J Kidney Dis* 2006; **48**: 392–401. MA
- 403 Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. *J Am Soc Nephrol* 2005; **16**: 1141–1148. OS
- 404 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 1984; **310**: 356–360. OS
- 405 Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; **63**: 225–232. RT
- 406 Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001; **286**: 421–426. OS
- 407 Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; **106**: 1777–1782. OS
- 408 Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S, Kawanami T, Tajima K, Daimon M, Kato T. Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. *J Neurol Sci* 2007; **255**: 27–34. OS
- 409 Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. *Diabetes Care* 2006; **29**: 595–600. CT
- 410 Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. *JAMA* 2007; **298**: 2038–2047. OS
- 411 Yokoyama H, Kawai K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). *Diabetes Care* 2007; **30**: 989–992. OS
- 412 Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. *Nat Clin Pract Nephrol* 2007; **3**: 428–438. RV
- 413 Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore Jr J, Reisin E, Ritz E, Scherthaner G, Spitalowitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. *J Am Soc Nephrol* 2005; **16**: 3027–3037. CT
- 414 Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. *Diabetes* 2007; **56**: 1727–1730. OS
- 415 Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A, Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). *Diabetes Care* 2007; **30**: 1581–1583. CT
- 416 Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. *Diabetes Care* 2007; **30**: 1577–1578. RT
- 417 Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. *Hypertens Res* 2007; **30**: 325–334. RT
- 418 Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int* 2004; **65**: 1870–1876. OS
- 419 Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. *Kidney Int* 2002; **62**: 956–962. OS
- 420 Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int* 2001; **59**: 1498–1509. OS
- 421 Orth SR. Smoking and the kidney. *J Am Soc Nephrol* 2002; **13**: 1663–1672.
- 422 Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. *Kidney Int* 2006; **69**: 2057–2063. OS
- 423 Japanese Society of Nephrology. Guidelines for life style and dietary therapy for kidney diseases. The Japanese Society of Nephrology. *Nippon Jinzo Gakkai Shi* 1997; **39**: 1–37. Japanese. GL
- 424 Nakao T, Sanaka T, Tsubakihara Y, Hattori M, Honda M, Mizuiri S, Watanabe Y, Kanazawa Y, Kanno T. Dietary recommendations for chronic kidney disease, 2007. *Nippon Jinzo Gakkai Shi* 2007; **49**: 871–878. Japanese. GL
- 425 Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. *Ann Intern Med* 1996; **124**: 627–632. MA

- 426 Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 2003; **139**: 244–252. MA
- 427 Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S, Modification of Diet in Renal Disease Study group. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? *J Am Soc Nephrol* 1999; **10**: 2426–2439. CT
- 428 Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. *Lancet* 2005; **366**: 2026–2033. MA
- 429 Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002; **288**: 2421–2431. RT
- 430 Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. *Am J Kidney Dis* 2007; **49**: 12–26. RV
- 431 PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. *J Hypertens* 2002; **20**: 729–737. RT
- 432 Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. *J Hypertens* 2007; **25**: 1921–1926. RT
- 433 MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. *Am J Kidney Dis* 2006; **48**: 8–20. MA
- 434 Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. *Ann Intern Med* 2008; **148**: 30–48. MA
- 435 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; **345**: 851–860. RT
- 436 Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E, Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. *Circulation* 2006; **114**: 26–31. RT
- 437 Ruggenenti P, Perna A, Remuzzi G, GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. *Kidney Int* 2003; **63**: 2254–2261. RT
- 438 de Zeeuw D. Albuminuria, just a marker for cardiovascular disease, or is it more? *J Am Soc Nephrol* 2005; **16**: 1883–1885.
- 439 Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; **33**: 1004–1010. GL
- 440 Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 2004; **43**: S1–S290. GL
- 441 Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003; **41**: 64–68. CT
- 442 Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. *Kidney Int* 2006; **70**: 2116–2123. RT
- 443 Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardi D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G, REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005; **365**: 939–946. RT
- 444 Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. *Diabetes Res Clin Pract* 2001; **54**: 191–201. RT
- 445 Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. *Am J Hypertens* 2003; **16**: 116–122. RT
- 446 Katayama K, Nomura S, Ishikawa H, Murata T, Kobayashi S, Nakano T. Comparison between valsartan and valsartan plus cilindipine in type II diabetics with normo- and microalbuminuria. *Kidney Int* 2006; **70**: 151–156. RT
- 447 Ogawa S, Mori T, Nako K, Ito S. Combination therapy of renin-angiotensin system inhibitors and calcium channel blocker, azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. *Hypertens Res* 2008; **31**: 1147–1155.
- 448 Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P, Medical Directors of Dialysis Clinic, Inc.. 'U' curve association of blood pressure and mortality in hemodialysis patients. *Kidney Int* 1998; **54**: 561–569. OS
- 449 Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. *Kidney Int* 2000; **58**: 2147–2154. OS
- 450 Iseki K, Miyasato F, Tokuyama K. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int* 1997; **51**: 1212–1217. RV
- 451 Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. *Clin J Am Soc Nephrol* 2007; **2**: 1228–1234. OS
- 452 Moriya H, Oka M, Maesato K, Mano T, Ikee R, Ohtake T, Kobayashi S. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. *Clin J Am Soc Nephrol* 2008; **3**: 416–422. OS
- 453 Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. *Kidney Int* 2002; **61**: 717–726. OS
- 454 Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int* 2004; **66**: 1212–1220.
- 455 Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. *Circulation* 2001; **103**: 987–992. CT
- 456 Kitahara T, Ono K, Tsuchida A, Kawai H, Shinohara M, Ishii Y, Koyanagi H, Noguchi T, Matsumoto T, Sekihara T, Watanabe Y, Kanai H, Ishida H, Nojima Y. Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients. *Am J Kidney Dis* 2005; **46**: 688–696. OS
- 457 London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. *J Am Soc Nephrol* 2001; **12**: 2759–2767. OS
- 458 Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). *Am J Kidney Dis* 2007; **49**: 426–431. OS
- 459 Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. *Kidney Int* 2002; **61**: 2157–2164.
- 460 Foley RN, Herzog CA, Collins AJ, United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. *Kidney Int* 2002; **62**: 1784–1790. OS
- 461 Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J. ACE inhibitors and survival of hemodialysis patients. *Am J Kidney Dis* 2002; **40**: 1023–1029. OS
- 462 Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. *Nephron* 2002; **90**: 256–261. RT
- 463 Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y. A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. *Adv Perit Dial* 2003; **19**: 59–66. RT
- 464 Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. *Am J Kidney Dis* 2005; **45**: 866–874. RT
- 465 Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. *Am J Kidney Dis* 2004; **43**: 1056–1064. RT
- 466 Japanese Circulation Society. Guidelines for Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection (JCS 2006). *Circ J* 2006; **70**: 1569–1646. Japanese. GL
- 467 Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson SG, Walker NM. Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet* 2002; **360**: 1531–1539. RT
- 468 Brewster DC, Cronenwett JL, Hallett JW, Johnston KW, Krupski WC, Matsumura JS, Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg* 2003; **37**: 1106–1117. GL
- 469 Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994; **330**: 1335–1341. RT
- 470 Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz III HC. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* 2008; **358**: 2787–2795. OS
- 471 Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L, Pediatric Heart Network Investigators. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. *Am Heart J* 2007; **154**: 624–631.
- 472 Hackam DG, Thiruchelvan D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. *Lancet* 2006; **368**: 659–665. OS
- 473 MacSweeney ST, Ellis M, Worrell PC, Greenhalgh RM, Powell JT. Smoking and growth rate of small abdominal aortic aneurysms. *Lancet* 1994; **344**: 651–652. RV

- 474 Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. *N Engl J Med* 2002; **347**: 1941–1951. RV
- 475 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg* 2007; **45** (Suppl S): S5–67. GL
- 476 Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med* 1991; **151**: 1769–1776. MA
- 477 Iimura O. Insulin resistance and hypertension in Japanese. *Hypertens Res* 1996; **19**: S1–S8. RV
- 478 American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. *Diabetes Care* 1989; **12**: 573–579. GL
- 479 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; **317**: 713–720. RT
- 480 Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. *Ann Intern Med* 1993; **118**: 577–581. RT
- 481 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2002; **25**: S5–20. GL
- 482 Ohnishi H, Saito S, Shimamoto K. Review of Tanno-Sobetsu chou study. *Ther Res* 2007; **28**: 513–525. Japanese. RV
- 483 Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. *Am J Hypertens* 1995; **8**: 353–357. CT
- 484 The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. *Lancet* 1997; **349**: 1787–1792. RT
- 485 J-MIND RESEARCH GROUP. Comparison of long-term effect of CA antagonist and ACE inhibitor on onset and development of diabetic nephropathy. *J Jpn Diabetes Soc* 1999; **42**: 5225.
- 486 Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; **345**: 870–878. RT
- 487 Viberti G, Wheelton NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002; **106**: 672–678. RT
- 488 Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. *Diabetes Care* 2001; **24**: 2091–2096. RT
- 489 Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *N Engl J Med* 1999; **340**: 677–684. RT
- 490 Estacio RO, Jeffers BW, Hiatt WR, Biggstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; **338**: 645–652. RT
- 491 Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; **21**: 597–603. RT
- 492 Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *Hypertension* 2006; **48**: 374–384. RT
- 493 Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney Int* 2008; **73**: 1303–1309. RT
- 494 Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. *Circ J* 2002; **66**: 1087–1095. OS
- 495 Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; **361**: 1149–1158. RT
- 496 The Ministry of Welfare, Japan. Report of the National Nutritional Survey in 1990. Tokyo: Daichi-Shuppan 1992. Japanese.
- 497 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486–2497. GL
- 498 Ohnishi H, Saitoh S, Takagi S, Katoh N, Chiba Y, Akasaka H, Nakamura Y, Shimamoto K. Incidence of Type 2 diabetes in individuals with central obesity in a rural Japanese population—The Tanno and Sobetsu Study. *Diabetes Care* 2006; **29**: 1128–1129.
- 499 Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. *Am J Respir Crit Care Med* 2001; **164**: 2147–2165. RV
- 500 Eguchi K, Kario K, Hoshida S, Ishikawa J, Morinari M, Shimada K. Nocturnal hypoxia is associated with silent cerebrovascular disease in a high-risk Japanese community-dwelling population. *Am J Hypertens* 2005; **18**: 1489–1495. OS
- 501 Wolk R, Somers VK. Sleep and the metabolic syndrome. *Exp Physiol* 2007; **92**: 67–78. RV
- 502 Sasanabe R, Banno K, Otake K, Hasegawa R, Usui K, Morita M, Shiomi T. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. *Hypertens Res* 2006; **29**: 315–322. OS
- 503 Shiina K, Tomiyama H, Takata Y, Usui Y, Asano K, Hirayama Y, Nakamura T, Yamashina A. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. *Hypertens Res* 2006; **29**: 433–441. OS
- 504 Endo S, Mataka S, Kurosaki N. Cephalometric evaluation of craniofacial and upper airway structures in Japanese patients with obstructive sleep apnea. *J Med Dent Sci* 2003; **50**: 109–120. OS
- 505 Sharafkhaneh A, Giray N, Richardson P, Young T, Hirshkowitz M. Association of psychiatric disorders and sleep apnea in a large cohort. *Sleep* 2005; **28**: 1405–1411. OS
- 506 Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. *Hypertension* 2003; **42**: 1067–1074. RV
- 507 Umlauf MG, Chasens ER, Greevy RA, Arnold J, Burgio KL, Pillion DJ. Obstructive sleep apnea, nocturia and polyuria in older adults. *Sleep* 2004; **27**: 139–144. OS
- 508 Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001; **19**: 2271–2277. OS
- 509 Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest* 1995; **96**: 1897–1904. OS
- 510 Pickering TG, Kario K. Nocturnal non-dipping: what does it augur? *Curr Opin Nephrol Hypertens* 2001; **10**: 611–616. RV
- 511 Kishimoto A, Tochikubo O, Ohshige K. Relation between nocturnal arterial oxygen desaturation and morning blood pressure. *Clin Exp Hypertens* 2007; **29**: 51–60. CT
- 512 Noda A, Nakata S, Koike Y, Miyata S, Kitaichi K, Nishizawa T, Nagata K, Yasuma F, Murohara T, Yokota M. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. *Hypertens Res* 2007; **30**: 669–676. RT
- 513 Möller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. *Am J Hypertens* 2003; **16**: 274–280. CT
- 514 Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, Seeger W, Grimminger F. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. *Am J Respir Crit Care Med* 2000; **162**: 566–570.
- 515 Yamauchi M, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Suzuki T, Kimura H. Oxidative stress in obstructive sleep apnea. *Chest* 2005; **127**: 1674–1679. OS
- 516 Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK. Elevated C-reactive protein in patients with obstructive sleep apnea. *Circulation* 2002; **105**: 2462–2464. CT
- 517 Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. *Am J Physiol Heart Circ Physiol* 2000; **279**: H234–H237. CT
- 518 Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. *Am J Respir Crit Care Med* 2002; **165**: 670–676. OS
- 519 Shirasaki O, Yamashita S, Kawara S, Tagami K, Ishikawa J, Shimada K, Kario K. A new technique for detecting sleep apnea-related 'midnight' surge of blood pressure. *Hypertens Res* 2006; **29**: 695–702.
- 520 Amin R, Somers VK, McConnell K, Willging P, Myer C, Sherman M, McPhail G, Morgenthal A, Fenchel M, Bean J, Kimball T, Daniels S. Activity-adjusted 24-hour ambulatory blood pressure and cardiac remodeling in children with sleep disordered breathing. *Hypertension* 2008; **51**: 84–91. CT
- 521 Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension* 2007; **50**: 417–423. MA
- 522 Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev* 2006; **3**: CD001106. MA
- 523 Doherty LS, Kiely JL, Swan V, McNicholas WT. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest* 2005; **127**: 2076–2084. OS

- 524 Marin JM, Carrizo SJ, Vicente E, Agustí AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; **365**: 1046–1053. OS
- 525 Barbé F, Mayoralas LR, Duran J, Masa JF, Maimó A, Montserrat JM, Monasterio C, Bosch M, Lladra A, Rubio M, Rubio R, Medinas M, Hernandez L, Vidal S, Douglas NJ, Agustí AG. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness: a randomized, controlled trial. *Ann Intern Med* 2001; **134**: 1015–1023. RT
- 526 Robinson GV, Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. *Eur Respir J* 2006; **27**: 1229–1235. RT
- 527 Kraiczai H, Hedner J, Peker Y, Grote L. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. *Am J Respir Crit Care Med* 2000; **161**: 1423–1428. RT
- 528 Pelttari LH, Hietanen EK, Salo TT, Kataja MJ, Kantola IM. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing. *Am J Hypertens* 1998; **11**: 272–279. RT
- 529 Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin A. Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest* 2007; **132**: 440–446. OS
- 530 Cicolin A, Mangiardi L, Mutani R, Bucca C. Angiotensin-converting enzyme inhibitors and obstructive sleep apnea. *Mayo Clin Proc* 2006; **81**: 53–55. OS
- 531 Hirota SA, Janssens LJ. Sodium and asthma: something borrowed, something new? *Am J Physiol Lung Cell Mol Physiol* 2007; **293**: L1369–L1373.
- 532 Arai T, Yasuda Y, Toshima S, Yoshimi N, Kashi Y. ACE inhibitors and pneumonia in elderly people. *Lancet* 1998; **352**: 1937–1938.
- 533 Okaishi K, Morimoto S, Fukuo K, Niinobu T, Hata S, Onishi T, Ogiwara T. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. *Am J Hypertens* 1999; **12**: 778–783. CT
- 534 Andreas S, Herrmann-Lingen C, Raupach T, Lüthje L, Fabricius JA, Hruska N, Körber W, Büchner B, Crieé CP, Hasenfuss G, Calverley P. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. *Eur Respir J* 2006; **27**: 972–979. RT
- 535 Cheng JW, Zhu L, Gu MJ, Song ZM. Meta analysis of propranolol effects on gastrointestinal hemorrhage in cirrhotic patients. *World J Gastroenterol* 2003; **9**: 1836–1839. MA
- 536 Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. *Hepatology* 2004; **40**: 1222–1225. OS
- 537 Japanese Society of Gout and Nucleic Acid Metabolism. *Guideline for the management of hyperuricemia and gout*. Japanese Society of Gout and Nucleic Acid Metabolism: Tokyo, 2002, p 79. Japanese. GL
- 538 Iwanaga T, Sato M, Maeda T, Ogiwara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. *J Pharmacol Exp Ther* 2007; **320**: 211–217.
- 539 Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyama M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002; **417**: 447–452.
- 540 Højieggan A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B, LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney Int* 2004; **65**: 1041–1049. RT
- 541 Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. *Lancet* 2000; **355**: 175–180.
- 542 Rastas S, Piirttilä T, Viramo P, Verkoniemi A, Halonen P, Juva K, Niinistö L, Mattila K, Lämsimies E, Sulkava R. Association between blood pressure and survival over 9 years in a general population aged 85 and older. *J Am Geriatr Soc* 2006; **54**: 912–918. OS
- 543 van Bommel T, Gussekloo J, Westendorp RG, Blauw GJ. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. *J Hypertens* 2006; **24**: 287–292. OS
- 544 Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, Leonetti G, Tuomilehto J, Yodfat Y. On-treatment diastolic blood pressure and prognosis in systolic hypertension. *Arch Intern Med* 2007; **167**: 1884–1891. OS
- 545 Ogiwara T, Rakugi H. Hypertension in the elderly: a Japanese perspective. *Drugs Aging* 2005; **22**: 297–314. RV
- 546 Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-analysis. *Ann Intern Med* 1994; **121**: 355–362. MA
- 547 Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, Hwang CT, Ruff DA, Montoro R, DeQuattro V, Zhang D, Schleman MM, Klibaner MI. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. *Hypertension* 2001; **38**: 1118–1123. RT
- 548 JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). *Hypertens Res* 2008; **31** (in press) RT
- 549 Perry Jr HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 2000; **284**: 465–471. RT
- 550 Kjeldsen SE, Kollock RE, Leonetti G, Mallion JM, Zanchetti A, Elmfield D, Warnold I, Hansson L. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. *J Hypertens* 2000; **18**: 629–642. RT
- 551 Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. *Arch Intern Med* 1999; **159**: 2004–2009. OS
- 552 Ogiwara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. *Am J Hypertens* 2000; **13**: 461–467. CT
- 553 Motoyama M, Sunami Y, Kinoshita F, Kiyonaga A, Tanaka H, Shindo M, Irie T, Urata H, Sasaki J, Arakawa K. Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. *Med Sci Sports Exerc* 1998; **30**: 818–823.
- 554 Hiwada K, Ogiwara T, Matsumoto M, Matsuoka H, Takishita S, Shimamoto K, Toba K, Abe I, Kohara K, Morimoto S, Mikami H, Iwai K, Takasaki M, Kawano Y, Higashiura K, Kozaki K, Eto M, Fujishima M. Guidelines for hypertension in the elderly—1999 revised version. Ministry of Health and Welfare of Japan. *Hypertens Res* 1999; **22**: 231–259. GL
- 555 Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremadura B, Gierard X, Laks T, Lilov E, Moiseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet* 1998; **352**: 1347–1351. RT
- 556 Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; **288**: 1491–1498. CT
- 557 Papademetriou V, Farsang C, Elmfield D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A. Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). *J Am Coll Cardiol* 2004; **44**: 1175–1180. CT
- 558 Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 2003; **348**: 583–592. RT
- 559 Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Geleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008; **336**: 1121–1123. MA
- 560 Berthet K, Neal BC, Chalmers JP, MacMahon SW, Boussier MG, Colman SA, Woodward M, Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. *Blood Press* 2004; **13**: 7–13. RT
- 561 Lindholm LH, Hansson L, Ekblom T, Dahlöf B, Lanke J, Linjer E, Scherstén B, Wester PO, Hedner T, de Faire U, STOP Hypertension-2 Study Group. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. *J Hypertens* 2000; **18**: 1671–1675. RT
- 562 Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruolpe LM, INSIGHT. Outcomes with nifedipine GITS or Co-amlozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). *Hypertension* 2003; **41**: 431–436. RT
- 563 Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2005; **165**: 1401–1409. RT
- 564 Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Caruthers G, Culleton B, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Touyz RM, Tobe SW, Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. *Can J Cardiol* 2007; **23**: 539–550. GL
- 565 Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Pettiti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith Jr SC, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK, Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *J Am Coll Cardiol* 2007; **49**: 1230–1250. GL

- 566 Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. *Nat Clin Pract Nephrol* 2007; **3**: 613–622. RV
- 567 The Guideline Committee of the Japanese Society of Obstetrics & Gynecology for Perinatal Medicine. Definition and classification of pregnancy-induced hypertension. *Nippon Sanka Fujinka Gakkai Zasshi* 2004; **56**: 12–13. Japanese
- 568 Waugh J, Perry IJ, Halligan AW, De Swiet M, Lambert PC, Penny JA, Taylor DJ, Jones DR, Shennan A. Birth weight and 24-hour ambulatory blood pressure in nonproteinuric hypertensive pregnancy. *Am J Obstet Gynecol* 2000; **183**: 633–637. OS
- 569 Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. *Cochrane Database Syst Rev* 2001 CD002252. RV
- 570 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet* 2005; **365**: 785–799. RV
- 571 Sibai BM. Chronic hypertension in pregnancy. *Obstet Gynecol* 2002; **100**: 369–377. RV
- 572 von Döbeln P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated meta-regression analysis. *J Obstet Gynaecol Can* 2002; **24**: 941–945. MA
- 573 Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. *N Engl J Med* 1996; **335**: 226–232. OS
- 574 Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. *Cochrane Database Syst Rev* 2002 CD003106. RV
- 575 von Döbeln P, Menzies J, Gilgoff S, Xie F, Douglas MJ, Sawchuck D, Magee LA. Evidence-based management for preeclampsia. *Front Biosci* 2007; **12**: 2876–2889. RV
- 576 Aali BS, Nejad SS. Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. *Acta Obstet Gynecol Scand* 2002; **81**: 25–30. RT
- 577 Montán S. Drugs used in hypertensive diseases in pregnancy. *Curr Opin Obstet Gynecol* 2004; **16**: 111–115. RV
- 578 Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. *Am J Med* 1994; **96**: 451–456. MA
- 579 From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. *JAMA* 1997; **277**: 1193–1194.
- 580 Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. *Cochrane Database Syst Rev* 2007 CD004451. RV
- 581 Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. *Cochrane Database Syst Rev* 2007 CD004659. MA
- 582 Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. *Cochrane Database Syst Rev* 2003 CD000025. RV
- 583 Briggs GG, Freeman RK, Yaffe SJ. *Drugs in Pregnancy and Lactation*, 8th edn. Lippincott Williams & Wilkins: Philadelphia, 2008.
- 584 Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. *Hypertension* 2004; **43**: 918–923. RV
- 585 Beale CM, Collins P. The menopause and the cardiovascular system. *Baillieres Clin Obstet Gynaecol* 1996; **10**: 483–513. RV
- 586 Oparil S. Hypertension in postmenopausal women: pathophysiology and management. *Curr Opin Nephrol Hypertens* 1995; **4**: 438–442. RV
- 587 Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. *J Hum Hypertens* 1998; **12**: 587–592. RV
- 588 Pines A, Fisman EZ. Hypertension in menopausal women—a special case, for special treatment? *Gynecol Endocrinol* 2001; **15**: 397–405. RV
- 589 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002; **288**: 321–333. RT
- 590 Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oral contraceptives and hypertension among women in the United States. *Circulation* 1996; **94**: 483–489. OS
- 591 Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; **291**: 1701–1712. RT
- 592 Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR, Zimpelmann J, Gao W, Catran DC, Scholey JW. Gender differences in the renal response to renin-angiotensin system blockade. *J Am Soc Nephrol* 2006; **17**: 2554–2560. CT
- 593 Tominaga T, Suzuki H, Ogata Y, Matsukawa S, Saruta T. The role of sex hormones and sodium intake in postmenopausal hypertension. *J Hum Hypertens* 1991; **5**: 495–500.
- 594 Fernández-Vega F, Abellán J, Vegazo O, García de Vinuesa S, Rodríguez JC, Maceira B, Sanz de Castro S, Robles NR, Luño J. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. *Kidney Int* 2002; **62** (Suppl 82): 36–41. OS
- 595 Deroo BJ, Korach KS. Estrogen receptors and human disease. *J Clin Invest* 2006; **116**: 561–570. RV
- 596 Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet* 2005; **366**: 1797–1803. OS
- 597 Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. *Clin Exp Nephrol* 2008; **12**: 102–109. RV
- 598 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; **114**: 555–576. GL
- 599 Uchiyama M. Topics and issues of pediatric hypertension. *J Child Health* 2005; **64**: 729–736. Japanese
- 600 Kikuchi T, Nagasaki K, Hiura M, Ogawa Y, Tanaka Y, Uchiyama M. Epidemiological approach to the childhood obesity. *J Japan Society for the Study of Obesity* 2004; **10**: 12–17. Japanese.
- 601 Hashimoto N, Kawasaki T, Kikuchi T, Takahashi H, Uchiyama M. The relationship between the intrauterine environment and blood pressure in 3-year-old Japanese children. *Acta Paediatr* 1996; **85**: 132–138.
- 602 Miura K, Nakagawa H, Tabata M, Morikawa Y, Nishijo M, Kagamimori S. Birth weight, childhood growth, and cardiovascular disease risk factors in Japanese aged 20 years. *Am J Epidemiol* 2001; **153**: 783–789. OS
- 603 Abe Y, Kikuchi T, Nagasaki K, Hiura M, Tanaka Y, Ogawa Y, Uchiyama M. Lower birth weight associated with current overweight status is related with the metabolic syndrome in obese Japanese children. *Hypertens Res* 2007; **30**: 627–634. OS
- 604 Stabouli S, Kotsis V, Zakopoulos N. Ambulatory blood pressure monitoring and target organ damage in pediatrics. *J Hypertens* 2007; **25**: 1979–1986. RV
- 605 Uchiyama M. Risk factors for the development of essential hypertension: long-term follow-up study in junior high school students in Niigata, Japan. *J Hum Hypertens* 1994; **8**: 323–325. OS
- 606 Kawasaki T, Uezono K, Sanefuji M, Utsunomiya H, Fujino T, Kanaya S, Babazono A. A 17-year follow-up study of hypertensive and normotensive male university students in Japan. *Hypertens Res* 2003; **26**: 445–452. CT
- 607 Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens* 1995; **8**: 657–665. OS
- 608 Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. *N Engl J Med* 2006; **354**: 2368–2374. RV
- 609 Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension* 2006; **47**: 846–853. OS
- 610 Kario K. *Clinician's manual on early morning risk management in hypertension*. Science Press: London, 2004, pp 1–68.
- 611 Obara T, Ohkubo T, Kikuya M, Asayama K, Metoki H, Inoue R, Oikawa T, Komai R, Murai K, Horikawa T, Hashimoto J, Totsumi K, Imai Y, J-HOME Study Group. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan Home versus Office Measurement Evaluation Study. *Blood Press Monit* 2005; **10**: 311–316. OS
- 612 Tomiyama M, Horio T, Yoshii M, Takiuchi S, Kamide K, Nakamura S, Yoshihara F, Nakahama H, Inenaga T, Kawano Y. Masked hypertension and target organ damage in treated hypertensive patients. *Am J Hypertens* 2006; **19**: 880–886. OS
- 613 Matsui Y, Eguchi K, Ishikawa J, Hoshida S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. *Am J Hypertens* 2007; **20**: 385–391. CT
- 614 Björklund K, Lind L, Zethelius B, Andrén B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation* 2003; **107**: 1297–1302. OS
- 615 Ishikawa J, Kario K, Eguchi K, Morinari M, Hoshida S, Ishikawa S, Shimada K, J-MORE Group. Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) study. *Hypertens Res* 2006; **29**: 679–686. OS
- 616 Mallion JM, Clerson P, Bobrie G, Genes N, Vaisse B, Chatellier G. Predictive factors for masked hypertension within a population of controlled hypertensives. *J Hypertens* 2006; **24**: 2365–2370. OS
- 617 Takagi T, Ohishi M, Ito N, Kaibe M, Tataru Y, Terai M, Shiota A, Hayashi N, Rakugi H, Ogihara T. Evaluation of morning blood pressure elevation and autonomic nervous activity in hypertensive patients using wavelet transform of heart rate variability. *Hypertens Res* 2006; **29**: 977–987. OS
- 618 Gosse P, Lasserre R, Minifié C, Lemetayer P, Clementy J. Blood pressure surge on rising. *J Hypertens* 2004; **22**: 1113–1118. OS
- 619 Kuwajima I, Mitani K, Miyao M, Suzuki Y, Kuramoto K, Ozawa T. Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients: relation to arising time. *Am J Hypertens* 1995; **8**: 29–33. OS
- 620 Polónia J, Amado P, Barbosa L, Nazaré J, Silva JA, Bertoquini S, Martins L, Carmona J. Morning rise, morning surge and daytime variability of blood pressure and cardiovascular target organ damage. A cross-sectional study in 743 subjects. *Rev Port Cardiol* 2005; **24**: 65–78. OS
- 621 Marfella R, Siniscalchi M, Portoghesi M, Di Filippo C, Ferraraccio F, Schiattarella C, Crescenzi B, Sanguolo P, Ferraro G, Siciliano S, Cinone F, Mazzarella G, Martis S, Verza M, Coppola L, Rossi F, D'Amico M, Paolisso G. Morning blood pressure surge as

- a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. *Hypertension* 2007; **49**: 784–791.
- 622 Shibuya Y, Ikeda T, Gomi T. Morning rise of blood pressure assessed by home blood pressure monitoring is associated with left ventricular hypertrophy in hypertensive patients receiving long-term antihypertensive medication. *Hypertens Res* 2007; **30**: 903–911. OS
- 623 Murakami S, Otsuka K, Kubo Y, Shinagawa M, Yamanaka T, Ohkawa S, Kitaura Y. Repeated ambulatory monitoring reveals a Monday morning surge in blood pressure in a community-dwelling population. *Am J Hypertens* 2004; **17**: 1179–1183. OS
- 624 Nagai M, Hoshida S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. *J Hypertens* 2008; **26**: 1636–1641. OS
- 625 Hoshida S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. *Hypertens Res* 2007; **30**: 143–149. OS
- 626 Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. *Hypertension* 2007; **50**: 333–339. OS
- 627 Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. *Circulation* 1999; **100**: 1635–1638. CT
- 628 Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. *Hypertension* 2008; **51**: 69–76. RT
- 629 Kario K, James GD, Marion R, Ahmed M, Pickering TG. The influence of work- and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women. *Hypertens Res* 2002; **25**: 499–506. OS
- 630 Yamasaki F, Schwartz JE, Gerber LM, Warren K, Pickering TG. Impact of shift work and race/ethnicity on the diurnal rhythm of blood pressure and catecholamines. *Hypertension* 1998; **32**: 417–423. OS
- 631 Kaplan NM. Hypertensive crises. In: *Kaplan's Clinical Hypertension*, 9th edn. Lippincott Williams & Wilkins: Baltimore, 2006, pp 311–324.
- 632 Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. *J Hypertens* 2006; **24**: 2482–2485. RV
- 633 Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet* 2000; **356**: 411–417. RV
- 634 JCS Joint Working Groups for Guidelines for Diagnosis and Treatment of Cardiovascular Diseases. Guidelines for Treatment of Acute Heart Failure (JCS 2006). http://www.j-circ.or.jp/guideline/pdf/JCS2006_maryama_h.pdf GL
- 635 Sesoko S, Akema N, Matsukawa T, Kaneko Y. Predisposing factors for the development of malignant essential hypertension. *Arch Intern Med* 1987; **147**: 1721–1724. CT
- 636 Ohta Y, Tsuchihashi T, Ohya Y, Fujii K, Hirakata H, Abe I, Fujishima M. Trends in the pathophysiological characteristics of malignant hypertension. *Hypertens Res* 2001; **24**: 489–492. CT
- 637 Kawazoe N, Eto T, Abe I, Takishita S, Ueno M, Kobayashi K, Uezono K, Muratani H, Kimura Y, Tomita Y. Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis. *Clin Nephrol* 1988; **29**: 53–57. OS
- 638 Kaplan NM. Functional somatic disease. In: *Clinical Hypertension*, 9th edn. Lippincott Williams & Wilkins: Baltimore, 2006, pp 451–453.
- 639 Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. *Arch Intern Med* 1999; **159**: 670–674. OS
- 640 Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith Jr SC, Jacobs AK, Anderson CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation* 2007; **116**: e418–e499. GL
- 641 Herman WW, Konzelman JL, Prisant LM. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New national guidelines on hypertension: a summary for dentistry. *J Am Dent Assoc* 2004; **135**: 576–584. GL
- 642 Tsuchihashi T, Takata Y, Kurokawa H, Miura K, Maruoka Y, Kajiyama M, Fujishima M. Blood pressure response during dental surgery. *Hypertens Res* 1996; **19**: 189–194. OS
- 643 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPA Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; **48**: 2293–2300. OS
- 644 Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? *Endocr J* 2007; **54**: 487–495. RV
- 645 Omae T. Pathophysiology and fate of hypertensive subjects. *Nippon Naika Gakkai Zasshi* 1985; **74**: 401–415. Japanese.
- 646 Berglund G, Andersson O, Wilhelmson L. Prevalence of primary and secondary hypertension: studies in a random population sample. *Br Med J* 1976; **2**: 554–556. OS
- 647 Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. *Arch Intern Med* 1987; **147**: 1289–1293. OS
- 648 Kimura G, Brenner BM. The renal basis for salt sensitivity in hypertension. In: Laragh JH & Brenner BM (eds). *Hypertension: Pathophysiology, Diagnosis and Management*, 2nd edn. Raven Press: New York, 1995, pp 1569–1588.
- 649 Kimura G. Glomerular function reserve and sodium sensitivity. *Clin Exp Nephrol* 2005; **9**: 102–113. RV
- 650 Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. *JAMA* 2000; **284**: 2622–2624. OS
- 651 Usami T, Sato R, Yoshida A, Kimura G. Regional variation in end-stage renal disease. *Curr Opin Nephrol Hypertens* 2002; **11**: 343–346. RV
- 652 Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, Kimura G. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. *Kidney Int* 2003; **64**: 1445–1449. OS
- 653 Blythe WB. Natural history of hypertension in renal parenchymal disease. *Am J Kidney Dis* 1985; **5**: A50–A56. RV
- 654 Konishi Y, Imanishi M, Okamura M, Yoshioka K, Okumura M, Okada N, Tanaka S, Fujii S, Kimura G. Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. *J Hypertens* 2000; **18**: 103–109.
- 655 Preston RA, Singer I, Epstein M. Renal Parenchymal Hypertension: current concepts of pathogenesis and management. *Arch Intern Med* 1996; **156**: 602–611. RV
- 656 Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. *J Am Soc Nephrol* 2003; **14**: 3217–3232. RV
- 657 Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccalà A, Zucchelli P. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. *Nephrol Dial Transplant* 1994; **9**: 265–269. RT
- 658 Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. *BMJ* 1989; **299**: 703–706. OS
- 659 Kincaid-Smith P. Glomerular lesions in atrophic pyelonephritis and reflux nephropathy. *Kidney Int Suppl* 1975; **4**: S81–S83.
- 660 Guidelines For Diagnosis And Treatment Of Autosomal Dominant Polycystic Kidney Disease. 2nd. In *Polycystic Kidney Disease*. Intermedica: Tokyo, 2006, 293–313. Japanese. GL
- 661 Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y. Genotypes of autosomal dominant polycystic kidney disease in Japanese. *J Hum Genet* 2002; **47**: 51–54.
- 662 Higashihara E, Nuthara K, Kojima M, Takakoshi A, Yoshiyuki O, Sakai H, Kurokawa K. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. *Nephron* 1998; **80**: 421–427.
- 663 Higashihara E, Aso Y, Shimazaki J, Ito H, Koiso K, Sakai O. Clinical aspects of polycystic kidney disease. *J Urol* 1992; **147**: 329–332.
- 664 Kelleher CL, McFann KK, Johnson AM, Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. *Am J Hypertens* 2004; **17**: 1029–1034. OS
- 665 Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. *N Engl J Med* 1990; **323**: 1091–1096. OS
- 666 Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med* 1996; **334**: 939–945. RT
- 667 Eder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 2000; **35**: 427–432. RT
- 668 van Dijk MA, Breuning MH, Duizer R, van Es LA, Westendorp RG. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. *Nephrol Dial Transplant* 2003; **18**: 2314–2320. RT
- 669 Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. *Kidney Int* 2005; **67**: 265–271. MA
- 670 Nuthara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. *Nephron Clin Pract* 2005; **99**: c18–c23. RT
- 671 Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Eder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. *J Am Soc Nephrol* 2002; **13**: 1733–1739. RT
- 672 Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME, Modification of Diet in Renal Disease Study Group. Dietary protein

- restriction, blood pressure control, and the progression of polycystic kidney disease. *J Am Soc Nephrol* 1995; **5**: 2037–2047. RT
- 673 Safian RD, Textor SC. Renal-artery stenosis. *N Engl J Med* 2001; **344**: 431–442. RV
- 674 Uzu T, Inoue T, Fujii T, Nakamura S, Inenaga T, Yutani C, Kimura G. Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. *Am J Kidney Dis* 1997; **29**: 733–738. OS
- 675 Kuroda S, Nishida N, Uzu T, Takeji M, Nishimura M, Fujii T, Nakamura S, Inenaga T, Yutani C, Kimura G. Prevalence of renal artery stenosis in autopsy patients with stroke. *Stroke* 2000; **31**: 61–65. OS
- 676 Yamashita T, Ito F, Iwakiri N, Mitsuyama H, Fujii S, Kitabatake A. Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. *Hypertens Res* 2002; **25**: 553–557. OS
- 677 Nakamura S, Iihara K, Matayoshi T, Yasuda H, Yoshihara F, Kamide K, Horio T, Miyamoto S, Kawano Y. The incidence and risk factors of renal artery stenosis in patients with severe carotid artery stenosis. *Hypertens Res* 2007; **30**: 839–844. OS
- 678 Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. *J Hypertens* 1997; **15**: 1365–1377. RV
- 679 Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. *Ann Intern Med* 1995; **122**: 833–838. CT
- 680 Rademacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med* 2001; **344**: 410–417. OS
- 681 Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. *Ann Intern Med* 2001; **135**: 401–411. MA
- 682 Tegtmeier CJ, Selby JB, Hartwell GD, Ayers C, Tegtmeier V. Results and complications of angioplasty in fibromuscular disease. *Circulation* 1991; **83**: 1155–1161.
- 683 Alhadad A, Mattiasson I, Ivancev K, Gottsäter A, Lindblad B. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. *J Hum Hypertens* 2005; **19**: 761–767.
- 684 Bonelli FS, McKusick MA, Textor SC, Kos PB, Stanson AW, Johnson CM, Sheedy II PF, Welch TJ, Schirger A. Renal artery angioplasty: technical results and clinical outcome in 320 patients. *Mayo Clin Proc* 1995; **70**: 1041–1052.
- 685 Zeller T, Frank U, Müller C, Bürgelin K, Sinn L, Bestehorn HP, Cook-Bruns N, Neumann FJ. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. *Circulation* 2003; **108**: 2244–2249. CT
- 686 van Jaarsveld BC, Krijnen P, Pieterman H, Derckx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in 't Veld AJ, Schalekamp MA, Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. *N Engl J Med* 2000; **342**: 1007–1014. OS
- 687 Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, Chew P, Gilbert SJ, Lau J. Effectiveness of management strategies for renal artery stenosis: a systematic review. *Ann Intern Med* 2006; **145**: 901–912. RV
- 688 Nordmann AJ, Logan AG. Balloon angioplasty versus medical therapy for hypertensive patients with renal artery obstruction. *Cochrane Database Syst Rev* 2003; CD002944. RV
- 689 Martin LG, Rundback JH, Sacks D, Cardella JF, Rees CR, Matsumoto AH, Meranze SG, Schwartzberg MS, Silverstein MI, Lewis CA, Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for angiography, angioplasty, and stent placement in the diagnosis and treatment of renal artery stenosis in adults. *J Vasc Interv Radiol* 2003; **14**: S297–S310. GL
- 690 Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. *J Hum Hypertens* 2006; **20**: 129–136. OS
- 691 Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. *Biomed Pharmacother* 2000; **54** (Suppl 1): 83s–85s. OS
- 692 Stowasser M, Gordon RD. Primary aldosteronism—careful investigation is essential and rewarding. *Mol Cell Endocrinol* 2004; **217**: 33–39.
- 693 Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. *Am J Kidney Dis* 1999; **33**: 261–266. OS
- 694 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM, Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2008; **93**: 3266–3281.
- 695 Gordon RD. Primary aldosteronism. *J Endocrinol Invest* 1995; **18**: 495–511. RV
- 696 Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. *J Clin Endocrinol Metab* 2003; **88**: 2489–2494. OS
- 697 Hiramoto K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiya T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. *Arch Intern Med* 1981; **141**: 1589–1593.
- 698 Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxford)* 2007; **66**: 607–618. RV
- 699 Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. *Am J Hypertens* 2002; **15**: 896–902. OS
- 700 Schirpenbach C, Seiler L, Maser-Gluth C, Rüdiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. *Eur J Endocrinol* 2006; **154**: 865–873. OS
- 701 Morimoto S, Takeda R, Murakami M. Does prolonged pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism? *J Clin Endocrinol Metab* 1970; **31**: 659–664. CT
- 702 The Japan Endocrine Society. http://square.umin.ac.jp/endocrine/rinsho_juyo/index.html.
- 703 Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. *Clin Endocrinol (Oxford)* 2004; **61**: 768–777. OS
- 704 Neumann HP, Cybulla M, Shibata H, Oya M, Naruse M, Higashihara E, Terachi T, Ling H, Takami H, Shuin T, Murai M. New genetic causes of pheochromocytoma: current concepts and the clinical relevance. *Keio J Med* 2005; **54**: 15–21. RV
- 705 Gornik HL, Creager MA. Aortitis. *Circulation* 2008; **117**: 3039–3051.
- 706 Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990; **33**: 1129–1134.
- 707 Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, Numano F. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. *J Nucl Med* 2005; **46**: 917–922.
- 708 Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis. *Circulation* 2003; **108**: 1474–1480. OS
- 709 Blaustein DA, Kumbar L, Srivastava M, Avram MM. Polyarteritis nodosa presenting as isolated malignant hypertension. *Am J Hypertens* 2004; **17**: 380–381. OS
- 710 Toro-Salazar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH. Long-term follow-up of patients after coarctation of the aorta repair. *Am J Cardiol* 2002; **89**: 541–547. OS
- 711 Kobayashi S, Yano M, Kohno M, Obayashi M, Hisamatsu Y, Ryoke T, Ohkusa T, Yamakawa K, Matsuzaki M. Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. *Circulation* 1996; **94**: 3362–3368.
- 712 Murakami T, Ueno M, Takeda A, Yakuwa S. Pressure wave reflection after successful balloon dilatation of aortic coarctation. *Circ J* 2007; **71**: 1821–1822. OS
- 713 Ross RD, Clapp SK, Gunther S, Paridon SM, Humes RA, Farooki ZQ, Pinsky WW. Augmented norepinephrine and renin output in response to maximal exercise in hypertensive coarctectomy patients. *Am Heart J* 1992; **123**: 1293–1299.
- 714 Jannetta PJ, Segal R, Wolfson SK. Neurogenic hypertension: etiology and surgical treatment. I. Observations in 53 patients. *Ann Surg* 1985; **201**: 391–398.
- 715 Morimoto S, Sasaki S, Takeda K, Furuya S, Naruse S, Matsumoto K, Higuchi T, Saito M, Nakagawa M. Decreases in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medulla in essential hypertension. *Stroke* 1999; **30**: 1707–1710. OS
- 716 Schobel HP, Frank H, Naraghi R, Geiger H, Titz E, Heusser K. Hypertension in patients with neurovascular compression is associated with increased central sympathetic outflow. *J Am Soc Nephrol* 2002; **13**: 35–41.
- 717 Smith PA, Meaney JF, Graham LN, Stoker JB, Mackintosh AF, Mary DA, Ball SG. Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. *J Am Coll Cardiol* 2004; **43**: 1453–1458.
- 718 Nicholas JS, D'Agostino SJ, Patel SJ. Arterial compression of the retro-olivary sulcus of the ventrolateral medulla in essential hypertension and diabetes. *Hypertension* 2005; **46**: 982–985.
- 719 Sendeski MM, Consolim-Colombo FM, Leite CC, Rubira MC, Lessa P, Krieger EM. Increased sympathetic nerve activity correlates with neurovascular compression at the rostral ventrolateral medulla. *Hypertension* 2006; **47**: 988–995.
- 720 Tan EK, Chan LL. Neurovascular compression syndromes and hypertension: clinical relevance. *Nat Clin Pract Neurol* 2007; **3**: 416–417. RV
- 721 Brown MJ. The causes of essential hypertension. *Br J Clin Pharmacol* 1996; **42**: 21–27. RT
- 722 Kato N, Miyata T, Tabara Y, Katsuya T, Yanai K, Hanada H, Kamide K, Nakura J, Kohara K, Takeuchi F, Mano H, Yasunami M, Kimura A, Kita Y, Ueshima H, Nakayama T, Soma M, Hata A, Fujioka A, Kawano Y, Nakao K, Sekine A, Yoshida T, Nakamura Y, Saruta T, Ogihara T, Sugano S, Miki T, Tomoike H. High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. *Hum Mol Genet* 2008; **17**: 617–627.
- 723 Yatsu K, Mizuki N, Hirawa N, Oka A, Itoh N, Yamane T, Ogawa M, Shiwa T, Tabara Y, Ohno S, Soma M, Hata A, Nakao K, Ueshima H, Ogihara T, Tomoike H, Miki T, Kimura A, Mano S, Kulski JK, Umemura S, Inoko H. High-resolution mapping for essential hypertension using microsatellite markers. *Hypertension* 2007; **49**: 446–452.
- 724 Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. *Hypertens Res* 2003; **26**: 521–525. RV
- 725 Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell* 2001; **104**: 545–556. RV
- 726 Ministry of Education. Ethics Guidelines for Human Genome/Gene Analysis Research. http://www.mext.go.jp/a_menu/shinkou/seimei/genome/04122801.htm.
- 727 Antman EM, Bennett JS, Daugherty A, Furburg C, Roberts H, Taubert KA, American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* 2007; **115**: 1634–1642. GL
- 728 Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in the Netherlands. *Drug Saf* 2008; **31**: 143–158. OS

- 729 Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? *Lancet* 2007; **370**: 2138–2151. RV
- 730 Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDs) in UK and USA populations. Implications for COX-2 cardiovascular profile. *Pharmacoepidemiol Drug Saf* 2006; **15**: 861–872. OS
- 731 Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. *Int J Toxicol* 2007; **26** (Suppl 2): 79–112. RV
- 732 Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2008; **47**: 72–75.
- 733 Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. *Am J Hypertens* 1995; **8**: 823–828.
- 734 Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. *Circ Res* 2003; **92**: 81–87. CT
- 735 Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyère F, Lebranchu Y. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. *Clin Transplant* 2007; **21**: 277–284. RT
- 736 Suzuki S, Aiya T. Research for preparing guidelines for criteria of Epo use. 1993, 165–172.
- 737 Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. *Hypertens Res* 2004; **27**: 79–84. CT
- 738 Ohkubo M, Ishimitsu T, Kawaguchi T, Abe M, Yagi S. Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia. *Nippon Jinzo Gakkai Shi* 1993; **35**: 171–177. Japanese.
- 739 Iseki K, Nakai S, Shinzato T, Morita O, Shinoda T, Kikuchi K, Wada A, Kimata N, Akiba T. Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. *Ther Apher Dial* 2007; **11**: 183–188. OS
- 740 Du Y, Melchert HU, Schäfer-Korting M. Use of oral contraceptives in Germany: prevalence, determinants and use-associated health correlates. Results of National Health Surveys from 1984 to 1999. *Eur J Obstet Gynecol Reprod Biol* 2007; **134**: 57–66. OS
- 741 Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. *Pharmacotherapy* 2000; **20**: 476–478. OS
- 742 Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with pheochromocytoma: incidence, prevention and management. *Drug Saf* 2007; **30**: 1031–1062. RV

KEY TO REFERENCES

CT: controlled trial; GL: guidelines/experts' opinion; MA: meta-analysis; OS: observational study; RT: randomized trial; RV: review.